中國太保(02601.HK)參與設立上海科創三期基金
格隆匯4月9日丨中國太保(02601.HK)公告,於2025年4月9日,太保壽險與上海科創、國際集團、虹橋睿智、上港集團、上海信託、建元信託及寧和盛諮詢共同簽訂上海科創三期基金合夥協議,擬設立上海科創三期基金。
上海科創三期基金的認繳出資總額擬定爲人民幣80億元,根據上海科創三期基金合夥協議,太保壽險(作爲有限合夥人)將對上海科創三期基金認繳出資人民幣8億元。
太保壽險參與上海科創三期基金的設立是貫徹落實國家創新驅動發展戰略、推動實現上海科創中心建設戰略目標的重要舉措。公司通過參與設立上海科創三期基金,雙方將進一步強化戰略協同和業務鏈接,共同服務上海科創中心和國際航運中心建設。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.